drugset
drugset / Trial / NCT06154187

Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis

NCT06154187 ↗

Phase 3 Unknown 60 enrolled Pharmbio Korea Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This clinical trial was multicenter, randomized, double-blind, placebo-controlled, parallel, phase III bridge study.

Timeline

Start
2024-02
Primary completion
2025-05
Completion
2025-11

Drugs

EvaluationDrugModalityDoseRoute
Subject PBK_L2201 Unknown 80 ug Subcutaneous

Indications

osteoporosis